In brief, through the combination therapy, the expressions of PD-L1 and IRF1 were significantly reduced in tumor tissues by CGA, and the interaction between PD-1 and PD-L1 was blocked by the antibody, thus the T cell mediated antitumor immunotherapy was promoted. The gene discussed is PDCD1; the disease is neoplasm.